Educational Content
Webcast: Rapid Development of Chemically Defined Media and Feeds through Replacement of Basal Hydrolysates
Protein hydrolysates are widely used in mammalian cell culture to improve cell growth and recombinant protein production. However, use of the hydrolysates can lead to significant process variability, due to the limited control of their source and final composition during manufacturing. On the other hand, development of chemically defined media and feeds requires a tremendous amount of work, including comprehensive library screening and spent media analysis.
In this educational webcast, Dr. Hao Chen, Associate Principal Scientist, BioProcess Development at Merck, describes a rapid method for developing chemically defined media and feeds for Chinese hamster ovary (CHO) cell lines from existing proprietary media and feeds by the replacement of basal protein hydrolysates with novel supplements.
Click here to view the webcast.
The Maturation of Single-Use Applications
Single-use systems (SUSs) have been treated as novel technologies for some time. Over the last 30 years, SUSs have evolved to become part of the biopharmaceutical development and production landscape and a mature, integrated option for bioprocessing. In this informative white paper, the author discusses the history, progression and future of SUSs. Click here to learn more.
Production of CGMP-Grade Lentiviral Vectors
Lentiviral vectors are important tools for gene transfer because of their ability to transduce a number of cell types without the need for host cells to be dividing. As a result, investigators are using them as gene delivery vehicles in clinical applications. Since lentiviral vectors play such a vital role in gene therapy, they need to be manufactured at large scale for clinical trials. But, large-scale production using CGMP methods can present a number of challenges. To address these challenges, the authors of this case study developed a process that allows for extensive scale-up in a safe, sterile, and reproducible system to produce clinical-grade lentivirus. Click here to learn more.
Differential Cell Culture Media for Single-Cell Cloning
Recombinant therapeutic protein production using cell culture systems is a $70 billion market. Most biotherapeutic proteins, including monoclonal antibodies (MAbs), are produced in Chinese hamster ovary (CHO) cells, which can generate the posttranslational modifications required for full biological function. Single-cell cloning is an important step in generating homogenous recombinant protein-producing mammalian cell lines. Recent advances in media development technologies have enabled limiting dilution cloning (LDC) and protein production in a serum-free environment to meet regulatory requirements. This case study compares the performance of various chemically defined (CD) serum-free media in LDC assay, clone expansion, and other parts of the bioprocessing work flow. Click here to learn more.
